DOCSLIB.ORG

The New Open-Access Journal for Outstanding Research in Life Science and Biomedicine

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The New Open-Access Journal for Outstanding Research in Life Science and Biomedicine About eLife.eLifesciences.org The new open-access journal for outstanding research in life science and biomedicine. eLife is a non-profit, researcher driven initiative to change peer review and improve the way research is presented and shared. eLife is the non-profit, joint • A unique collaboration between the • It’s free to publish with eLife for the initiative of the Howard funders and practitioners of research, eLife first few years. We’re making it as easy Hughes Medical Institute, is run by active scientists. Each of the 200 as possible to get important works out the Max Planck Society, members on our editorial board is among into the open. Submit now – there are and the Wellcome Trust to the most respected scientists in their field. currently no publishing fees. communicate influential discoveries in the most • We promote rapid, fair, and constructive effective way. The first review. Initial decisions are made in a few “There’s room at the top for a step in the initiative is days. For submissions selected for full more effective approach to to establish a new, open review, post-review decisions are access journal for the most delivered in less than a month – and include scientific publishing. eLife important advances in life and a consolidated decision letter with only delivers the highest quality biomedical sciences – from essential revision requests. basic biological research research and the most important to applied, translational • We publish ground-breaking research discoveries, while saving and clinical studies. The in all disciplines from human genetics eLife journal extends the and neuroscience to biophysics and precious time in the publication reach and influence of key epidemiology. process and ensuring maximum discoveries and showcases new approaches to the impact for results.” presentation, use, and Randy Schekman, Editor-in-Chief and assessment of research. Professor, UC Berkeley Publish your best work Now publishing key advances in: Biochemistry | Biophysics & structural biology | Cell biology with eLife today Developmental biology & stem cells | Ecology | Epidemiology & global health | Genes & chromosomes | Genomics & evolutionary biology | Human biology & medicine Immunology | Microbiology & infectious disease | Neuroscience | Plant biology Easy to comply with funder policies. As an open-access journal, eLife makes all published papers immediately and freely available online under a Creative Commons-Attribution (CC-BY) license. All content is immediately deposited into PubMed Central and Europe PubMed Central. Still waiting for that great paper to get through peer review? Then you didn’t submit it to . Supported by @eLife facebook.com/eLifesciences eLife.eLifesciences.org eLife.eLifesciences.org Editorial Leadership Our editors work closely together Editor-In-Chief Richard Losick, Harvard University (USA) to achieve eLife’s Randy Schekman, University of California at Microbiology & pathogens commitment to fast, Berkeley (USA) James Manley, Columbia University (USA) fair, and constructive Chromosomes & gene expression editorial decision- Deputy Editors making while only Eve Marder, Fiona Watt, Centre for Stem Cells and Brandeis University (USA) publishing the most Systems neuroscience influential advances Regenerative Medicine at King’s College in life science and London (UK) Michael Marletta, The Scripps Research biomedicine. The Institute (USA) Chemical biology R. Schekman Senior Editors and Detlef Weigel, Max Planck Institute for the 175-member Developmental Biology (Germany) Chris Ponting, University of Oxford (UK) Board of Reviewing Computational biology Senior Editors Editors represent Janet Rossant, University of Toronto (Canada) the wide array of Stylianos Antonarakis, University of Geneva Developmental biology disciplines targeted Medical School (Switzerland) Human genetics for the eLife journal – & genomics Charles Sawyers, Memorial Sloan-Kettering from human genetics Cancer Center (USA) Oncology & translational and neuroscience Ian Baldwin, Max Planck Institute for medicine to biophysics and Chemical Ecology (Germany) Evolutionary epidemiology. biology Tadatsugu Taniguchi, University of Tokyo (Japan) Senior Editor, Immunology F. Watt Catherine Dulac, Harvard University (USA) Cellular & molecular neuroscience K (Vijay) VijayRaghavan, Department of Biotechnology of the Government of India Joe Goldstein, University of Texas (India) Genetics & genomics Southwestern Medical Center (USA) Medical genetics, medical physiology & metabolism Xiaodong Wang, National Institute of Biological Sciences (China) Cell biology/ Tony Hunter, Cell Salk Institute (USA) medical physiology & Metabolism signaling & basic cancer biology Huda Zoghbi, Baylor College of Medicine Prabhat Jha, University of Toronto (Canada) (USA) Animal models of human disease & Epidemiology behavioural sciences D. Weigel John Kuriyan, University of California at Berkeley (USA) Biochemistry, biophysics, & structural biology Board of Reviewing Editors Salim Abdool Karim Giulio Cossu Todd Golub Roberto Kolter Michel Nussenzweig Yigong Shi Julie Ahringer Ben Cravatt Bruce Goode Robb Krumlauf Hideyuki Okano Robert Singer Asifa Akhtar Jody Culham Jean Greenberg Werner Kuhlbrandt Richard Palmiter Nahum Sonenberg Richard Aldrich Michael Czech Peter Greenberg Antonio Lanzavecchia Duojia Pan Deepak Srivastava James Allison Valerie Daggett Carol Greider Michael Laub Roy Parker John Richard Amasino Chi Dang Leslie Griffith Ruth Lehmann Mercedes Pascual Stamatoyannopoulos Dora Angelaki Robert B.Darnell Eduardo Groisman Beth Levine Sam Pfaff Louis Staudt Mohan Balasubramanian Graeme Davis Roderic Guigo Pat Levitt Suzanne Pfeffer Gisela Storz Andrea Ballabio Roger Davis Bin Han Michael Levitt Jon Pines Kevin Struhl Utpal Banerjee Bart De Strooper Greg Hannon Liqun Luo Kathrin Plath Wes Sundquist David Baulcombe Emmanouil Christian Hardtke Vivek Malhotra Franck Polleux Diethard Tautz Timothy Behrens Dermitzakis Maria Harrison Peggy Mason Fiona Powrie Stephen Tollman Dominique Bergmann Ray Deshaies Michael Häusser Joan Massague Carol Prives Peter Tontonoz Carl T. Bergstrom Marcel Dicke Nathaniel Heintz Diane Mathis Nick Proudfoot Misha Tsodyks Benjamin Blencowe Harry Dietz Helen Hobbs John Mattick Molly Przeworski Wilfred van der Donk Joerg Bohlmann Ivan Dikic Oliver Hobert Mark McCarthy Louis Ptacek Victor Velculescu Michael Botchan Volker Dotsch Jules Hoffmann Sheila McCormick Mani Ramaswami Gordana Vunjak- Axel Brakhage Peter A.Edwards Brigid Hogan Helen McNeill Rama Ranganathan Novakovic Andrea Brand Eichenbaum Tony Hyman Gil McVean Aviv Regev David Wallach Marianne Bronner Joaquin Howard Barbara Imperiali Ruslan Medzhitov Danny Reinberg Christopher T.Walsh Axel Brunger Espinosa Elisa Izaurralde Freda Miller Ranulfo Romo Johannes Walter Margaret Buckingham Anne Ferguson-Smith Reinhard Jahn Noboru Mizushima David Ron Karsten Weis Ron Calabrese Russ Fernald Leemor Joshua-Tor Todd Mockler Christian Rosenmund Gary Westbrook Zhijian ‘James’ Chen James Ferrell Jim Kadonaga Sean J.Morrison Benoit Roux Tanya Whitfield Arul Chinnaiyan Eduardo Franco Nancy Kanwisher Jeremy Nathans David Sabatini Richard J.Youle Joanne Chory Matthew Freeman Jeffrey Kelly Sacha Nelson Shimon Sakaguchi Stephen Young Jon Clardy Elaine Fuchs Philipp Khaitovich James Nelson Alejandro Sánchez Phil Zamore Philip Cole Thomas Gingeras Ole Kiehn Timothy Nilsen Alvarado Xiaowei Zhuang Jon Cooper David Ginsburg Eunjoon Kim Jodi Nunnari Sema Sgaier Pascale Cossart Christopher Glass Dan Kliebenstein Thorsten Nürnberger Feng Shao eLife Sciences Publications, Ltd is a limited liability non-profit non-stock corporation incorporated in the State of Delaware, USA, with company number 5030732, and is registered in the UK with company number FC030576 and branch number BR015634 at the address Suite 203, Sheraton House, Castle Park, Cambridge CB3 0AX. v1 – May 2013.
Load more

Recommended publications
  • Prospects and Challenges for the Global Nuclear Future: After Fukushima Scott D
    Spring_2012_COVER 4/23/2012 10:32 AM Page 3 american academy of arts & sciences spring 2012 www.amacad.org Bulletin vol. lxv, no. 3 Prospects and Challenges for the Global Nuclear Future: After Fukushima Scott D. Sagan, Harald Müller, Noramly bin Muslim, Olli Heinonen, and Jayantha Dhanapala The Future of the American Military Karl W. Eikenberry, John L. Hennessy, James J. Sheehan, David M. Kennedy, and William J. Perry ALSO: Patrick C. Walsh, M.D., Awarded the Francis Amory Prize Humanities Indicators Track Signi½cant Changes in the Disciplines Strengthening Energy Policy through Social Science WikiLeaks and the First Amendment Upcoming Events Special Thanks to Donors APRIL ore than $5.2 million was raised in the ½scal year completed on March 31, 25th M 2012. The Academy’s Annual Fund sur- Project Brie½ng–Washington, D.C. passed the $1.6 million mark for the ½rst The Alternative Energy Future time. Additional gifts and grants totaled Speakers: Steven Koonin (Institute for over $3.6 million, with more than 1,200 in- Defense Analyses; formerly, U.S. Depart- dividuals, 14 foundations, and 54 University ment of Energy); Robert Fri (Resources Af½liates contributing to make these results for the Future); Michael Graetz (Colum- possible. “This was a very successful year,” bia Law School); Michael Greenstone said Alan Dachs, Development and Public (Massachusetts Institute of Technology; Relations Committee Chair. “The Academy Brookings Institution); Kassia Yanosek is fortunate that so many Fellows support (Stanford University; Tana Energy the work we are doing.” Dachs expressed his Capital llc) deep appreciation to the members of the De- velopment Committee during the past year, MAY including Louise Bryson, Richard Cavanagh, 14th Jesse Choper, David Frohnmayer, Michael Reception–New York City Gellert, Matthew Santirocco, Stephen Reception in Honor of New York Area Fellows Stamas, Donald Stewart, Samuel Thier, and Nicholas Zervas, along with the continuing 16th involvement of Board Chair Louis Cabot.
    [Show full text]
  • ERC Advanced Grant 2008 Project Acronym Title Principal Investigator Host Institution Host Country 226037 NSYS Nonlinear System
    ERC Advanced Grant 2008 Project Acronym Title Principal Investigator Host Institution Host Country Nonlinear System Identification and Analysis in the Time, Prof. Stephen Alec 226037 NSYS THE UNIVERSITY OF SHEFFIELD UK Frequency, and Spatio-Temporal Domains Billings HOWTOCONT Search for mechanisms to control massless electrons in 226043 ROLGRAPHE Prof. Carlo Beenakker UNIVERSITEIT LEIDEN. NL graphene NE THE HEBREW UNIVERSITY OF 226135 EXPANDERS Expander Graphs in Pure and Applied Mathematics Prof. Alexander Lubotzky IL JERUSALEM. 226136 VISCHEM Visualizing Molecular Change Prof. Villy Sundström LUNDS UNIVERSITET SE Consistent computation of the chemistry-cloud THE CYPRUS RESEARCH AND 226144 C8 Prof. Johannes Lelieveld CY continuum and climate change in Cyprus EDUCATIONAL FOUNDATION Modern Approaches to Temperature Reconstructions in 226172 MATRICS Dr. Hubertus Fischer UNIVERSITAET BERN CH polar Ice Cores FUndamental studies and innovative appROaches of Prof. Roland Martin 226180 FURORE UNIVERSITAET HAMBURG DE REsearch on magnetism Wiesendanger EBERHARD KARLS 226187 SOCATHES Solid State/Cold Atom Hybrid Quantum Devices Prof. Reinhold Kleiner DE UNIVERSITAET TUEBINGEN KUNGLIGA TEKNISKA 226203 APPROXNP Approximation of NP-hard optimization problems Prof. Johan Håstad SE HOEGSKOLAN Patchy colloidal particles: a powerful arsenal for the PATCHYCOLL fabrication of tomorrow new super-molecules . A UNIVERSITA DEGLI STUDI DI 226207 Prof. Francesco Sciortino IT OIDS theoretical and numerical study of their assembly ROMA LA SAPIENZA processes. ERC Advanced Grant 2008 Analytic Techniques for Geometric and Functional UNIVERSITA DEGLI STUDI DI 226234 ANTEGEFI Prof. Nicola Fusco IT Inequalities NAPOLI FEDERICO II. Multiscale Models for Catalytic-Reaction-Coupled 226238 MMFCS Prof. Bengt Sundén LUNDS UNIVERSITET SE Transport Phenomena in Fuel Cells WEIZMANN INSTITUTE OF 226246 NANOSQUID Scanning Nano-SQUID on a Tip Prof.
    [Show full text]
  • Nature Medicine Essay
    COMMENTARY LASKER BASIC MEDICAL RESEARCH AWARD Of maize and men, or peas and people: case histories to justify plants and other model systems David Baulcombe One of the byproducts of molecular biology cork is altogether filled with air, and that air is has been support for the ‘model system’ con- perfectly enclosed in little boxes or cells distinct cept. All living organisms are based on the same from one another.”)2 (Fig. 1). Two hundred fifty genetic code, they have similar subcellular years later, Beijerinck discovered a contagium structures and they use homologous metabolic vivum fluidum in extracts of diseased tobacco pathways. So, mechanisms can be investigated plants that he later referred to as a virus3. using organisms other than those in which In contemporary science, a green alga— the knowledge will be exploited for practical Chlamydomonas reinhardtii—is a useful model benefit. Model systems are particularly use- in the analysis of kidney disease4. However, ful in the early discovery phase of a scientific in this article, I refer to the contribution of endeavor, and recent progress in biomedical plant biology to a family of mechanisms that I science has fully vindicated their use. Jacques refer to as RNA silencing. This topic has been Monod, for example, famously justified his reviewed comprehensively elsewhere5,6, so here work on a bacterial model system by stating I focus on personal experience and my view of that “what is true for Escherichia coli is also future potential from this work. true for elephants.” My fellow laureates, Victor Ambros and Gary Ruvkun, can defend the use The early history of RNA silencing in of the worm Caenorhabditis elegans as a good plants model system and so I will focus on plants.
    [Show full text]
  • Summaries of FY 2001 Activities Energy Biosciences
    Summaries of FY 2001 Activities Energy Biosciences August 2002 ABSTRACTS OF PROJECTS SUPPORTED IN FY 2001 (NOTE: Dollar amounts are for a twelve-month period using FY 2001 funds unless otherwise stated) 1. U.S. Department of Agriculture Urbana, IL 61801 Biochemical and molecular analysis of a new control pathway in assimilate partitioning Daniel R. Bush, USDA-ARS and Department of Plant Biology, University of Illinois at Urbana- Champaign $72,666 (21 months) Plant leaves capture light energy from the sun and transform that energy into a useful form in the process called photosynthesis. The primary product of photosynthesis is sucrose. Generally, 50 to 80% of the sucrose synthesized is transported from the leaf to supply organic nutrients to many of the edible parts of the plant such as fruits, grains, and tubers. This resource allocation process is called assimilate partitioning and alterations in this system are known to significantly affect crop productivity. We recently discovered that sucrose plays a second vital role in assimilate partitioning by acting as a signal molecule that regulates the activity and gene expression of the proton-sucrose symporter that mediates long-distance sucrose transport. Research this year showed that symporter protein and transcripts turn-over with half-lives of about 2 hr and, therefore, sucrose transport activity and phloem loading are directly proportional to symporter transcription. Moreover, we showed that sucrose is a transcriptional regulator of symporter expression. We concluded from those results that sucrose-mediated transcriptional regulation of the sucrose symporter plays a key role in coordinating resource allocation in plants. 2. U.
    [Show full text]
  • 2012 Annual Report
    Memorial Sloan-Kettering Cancer Center 2012 ANNUAL REPORT A SHARED VISION A SINGULAR MISSION Nurse practitioner Naomi Cazeau, of the Adult Bone Marrow Transplant Service. PING CHI PHYSICIAN-SCIENTIST 10 STEPHEN SOLOMON ALEXANDER RUDENSKY INTERVENTIONAL IMMUNOLOGIST RADIOLOGIST 16 12 VIVIANE TABAR The clinicians and scientists of NEUROSURGEON Memorial Sloan-Kettering share a vision and 18 a singular mission — to conquer cancer. STEPHEN LONG STRUCTURAL BIOLOGIST They are experts united against a 20 SIMON POWELL complex disease. Each type of cancer R ADIATION ONCOLOGIST 24 ETHEL LAW is different, each tumor is unique. Set free NURSE PRACTITIONER in surroundings that invite the sharing of 26 ideas and resources, they attack the CHRISTINA LESLIE complexity of cancer from every angle COMPUTATIONAL BIOLOGIST and every discipline. 34 SCOTT ARMSTRONG PEDIATRIC ONCOLOGIST 30 TO JORGE REIS-FILHO EXPERIMENTAL PATHOLOGIST CONQUER 38 CANCER 04 Letter from the Chairman and the President A complete version of this report — 42 Statistical Profile which includes lists of our donors, 44 Financial Summary doctors, and scientists — 46 Boards of Overseers and Managers is available on our website at 49 The Campaign for Memorial Sloan-Kettering www.mskcc.org/annualreport. 4 5 Letter from the Chairman In 2012 the leadership of Memorial Sloan-Kettering endorsed Douglas A. Warner III These programmatic investments require leadership and and the President a $2.2 billion investment in a clinical expansion that will set vision. Our new Physician-in-Chief, José Baselga, joined the stage for a changing care paradigm into the next decade us on January 1, 2013. An internationally recognized and beyond.
    [Show full text]
  • The BBVA Foundation Frontiers of Knowledge Award in Biomedicine Goes to Tony Hunter, Joseph Schlessinger and Charles Sawyers
    The BBVA Foundation Frontiers of Knowledge Award in Biomedicine goes to Tony Hunter, Joseph Schlessinger and Charles Sawyers for opening the door to the personalized treatment of cancer The winners represent the three steps in research leading to this advance: Tony Hunter discovered tyrosine kinases, Joseph Schlessinger identified the principle through which they function, and Charles Sawyers brought this knowledge to the clinic and the development of novel cancer therapies Their contributions served initially to treat a variety of leukemia, transforming it from a fatal into a chronic disorder, but have since given rise to effective therapies for lung and breast cancer, melanoma and lymphomas, among other conditions José Baselga, Physician-in-Chief at the Memorial Sloan Kettering Cancer Center in New York and nominator of Charles Sawyers, described the contributions of the three laureates as marking “the birth of personalized anti-cancer medicine” Madrid, January 27, 2015.- The BBVA Foundation Frontiers of Knowledge Award in the Biomedicine category is shared in this seventh edition by Tony Hunter, professor and Director of the Salk Institute Cancer Center in La Jolla, California; Joseph Schlessinger, Chairman of the Department of Pharmacology at Yale University School of Medicine, New Haven, and Charles Sawyers, Human Oncology and Pathogenesis Program Chair at the Memorial Sloan Kettering Cancer Center in New York, for “carving out the path that led to the development of a new class of successful cancer drugs.” For José Baselga, Physician-in-Chief
    [Show full text]
  • 3718 Issue63july2010 1.Pdf
    Issue 63.qxd:Genetic Society News 1/10/10 14:41 Page 1 JULYJULLYY 2010 | ISSUEISSUE 63 GENETICSGENNETICSS SOCIETYSOCIEETY NENEWSEWS In this issue The Genetics Society NewsNewws is edited by U Genetics Society PresidentPresident Honoured Honoured ProfProf David Hosken and items ittems for future future issues can be sent to thee editor,editor, preferably preferably U Mouse Genetics Meeting by email to [email protected],D.J.Hosken@@exeter.ac.uk, or U SponsoredSponsored Meetings Meetings hardhard copy to Chair in Evolutionary Evoolutionary Biology, Biology, UniversityUniversity of Exeter,Exeter, Cornwall Cornnwall Campus, U The JBS Haldane LectureLecture Tremough,Tremough, Penryn, TR10 0 9EZ UK.UK. The U Schools Evolutionn ConferenceConference Newsletter is published twicet a year,year, with copy dates of 1st June andand 26th November.November. U TaxiTaxi Drivers The British YeastYeaste Group Group descend on Oxford Oxford for their 2010 meeting: m see the reportreport on page 35. 3 Image © Georgina McLoughlin Issue 63.qxd:Genetic Society News 1/10/10 14:41 Page 2 A WORD FROM THE EDITOR A word from the editor Welcome to issue 63. In this issue we announce a UK is recognised with the award of a CBE in the new Genetics Society Prize to Queen’s Birthday Honours, tells us about one of Welcome to my last issue as join the medals and lectures we her favourite papers by Susan Lindquist, the 2010 editor of the Genetics Society award. The JBS Haldane Mendel Lecturer. Somewhat unusually we have a News, after 3 years in the hot Lecture will be awarded couple of Taxi Drivers in this issue – Brian and seat and a total of 8 years on annually to recognise Deborah Charlesworth are not so happy about the committee it is time to excellence in communicating the way that the print media deals with some move on before I really outstay aspects of genetics research to scientific issues and Chris Ponting bemoans the my welcome! It has been a the public.
    [Show full text]
  • Fire Departments of Pathology and Genetics, Stanford University School of Medicine, 300 Pasteur Drive, Room L235, Stanford, CA 94305-5324, USA
    GENE SILENCING BY DOUBLE STRANDED RNA Nobel Lecture, December 8, 2006 by Andrew Z. Fire Departments of Pathology and Genetics, Stanford University School of Medicine, 300 Pasteur Drive, Room L235, Stanford, CA 94305-5324, USA. I would like to thank the Nobel Assembly of the Karolinska Institutet for the opportunity to describe some recent work on RNA-triggered gene silencing. First a few disclaimers, however. Telling the full story of gene silencing would be a mammoth enterprise that would take me many years to write and would take you well into the night to read. So we’ll need to abbreviate the story more than a little. Second (and as you will see) we are only in the dawn of our knowledge; so consider the following to be primer... the best we could do as of December 8th, 2006. And third, please understand that the story that I am telling represents the work of several generations of biologists, chemists, and many shades in between. I’m pleased and proud that work from my labo- ratory has contributed to the field, and that this has led to my being chosen as one of the messengers to relay the story in this forum. At the same time, I hope that there will be no confusion of equating our modest contributions with those of the much grander RNAi enterprise. DOUBLE STRANDED RNA AS A BIOLOGICAL ALARM SIGNAL These disclaimers in hand, the story can now start with a biography of the first main character. Double stranded RNA is probably as old (or almost as old) as life on earth.
    [Show full text]
  • Unfolding Plant Disease Resistance : the Involvement of HSP90 and Its Co- Chaperone PP5 in I-2-Mediated Signalling De La Fuente Van Bentem, S
    UvA-DARE (Digital Academic Repository) Unfolding plant disease resistance : the involvement of HSP90 and its co- chaperone PP5 in I-2-mediated signalling de la Fuente van Bentem, S. Publication date 2005 Document Version Final published version Link to publication Citation for published version (APA): de la Fuente van Bentem, S. (2005). Unfolding plant disease resistance : the involvement of HSP90 and its co-chaperone PP5 in I-2-mediated signalling. General rights It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons). Disclaimer/Complaints regulations If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: https://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible. UvA-DARE is a service provided by the library of the University of Amsterdam (https://dare.uva.nl) Download date:05 Oct 2021 Unfolding plant disease resistance the involvement of HSP90 and its co-chaperone PP5 in I-2-mediated signalling ACADEMISCH PROEFSCHRIFT ter verkrijging van de graad van doctor aan de Universiteit van Amsterdam, op gezag van de Rector Magnificus prof.
    [Show full text]
  • 100Th RAF Raffle – Kurt Durlesser and Evan Garcia OHRPP Updates
    Marcia L. Smith November 14, 2019 2 Welcome & Announcements 2009 - 2019 3 4 Agenda • Office of the Human Research Protection Program ◦ Roll-out of PI and Faculty Assurances – Moore Rhys • Extramural Fund Management ◦ Closing Expired Funds – Will Murdoch ◦ ERS Listserv Changes – Will Murdoch ◦ Ascend: Expenditure Type – Yoon Lee • UCLA Trivia and 100th RAF Raffle – Kurt Durlesser and Evan Garcia OHRPP Updates November 14, 2019 – 100th RAF 2 OHRPP Updates Annual PI and FS Assurances Human Research News Training opportunities 3 Annual PI and Faculty Sponsor Assurances In order to keep track of active studies that don’t require continuing review, OHRPP has worked with ORIS to create a mechanism for a yearly check-in with investigators. 4 Annual PI and Faculty Sponsor Assurances These will be required (in lieu of continuing review) to continue the following types of research: • Certified exempt • Studies determined eligible for expedited review • Research that has progressed to the point of only collecting results of clinical care procedures/tests for follow-up • Research that has progressed to the point of data analysis only • Studies where a UCLA IRB is relying on another IRB 5 Annual PI and Faculty Sponsor Assurances Automatic email notices (with instructions) will be sent out from the webIRB system: - 9 months after the initial approval (or last annual assurance) – 3 months before the assurance is due - 10 months after the initial approval (or last annual assurance) – 2 months before the assurance is due - 11 months after the initial approval (or last annual assurance – 1 month before the assurance is due - 12 months after the initial approval (or last annual assurance) – the day the assurance is due 6 Annual PI and Faculty Sponsor Assurances Important: If the PI (and faculty sponsor, if applicable) doesn’t complete the annual assurance, the study will be administratively closed PI proxies cannot complete the assurance 7 Annual PI and Faculty Sponsor Assurances If the PI has a faculty sponsor, the faculty advisor must complete their assurance first.
    [Show full text]
  • Download Free from the Itunes App Store Today!
    HHMI BULLETIN F ALL ’12 V OL .25 • N O . 03 • 4000 Jones Bridge Road Chevy Chase, Maryland 20815-6789 Hughes Medical Institute Howard www.hhmi.org Out of Africa • This beauty is Aedes aegypti, a mosquito that can transmit www.hhmi.org dengue and yellow fever viruses, among others. Originally from Africa, it is now found in tropical and subtropical regions around the world. While this mosquito prefers to feast on animals over humans, it lives in close proximity to blood-hungry relatives that will choose a human meal every time. HHMI investigator Leslie Vosshall and her lab group are studying the evolutionary changes behind the insects’ diverse dietary habits. Their research may help reduce mosquito-borne illnesses. Read about Vosshall and the arc of her scientific career in “Avant Garde Scientist,” page 18. perils of fatty liver vosshall on the scent über cameras vol. vol. 25 / no. / no. Leslie Vosshall 03 ObservatiOns tHe traininG PiPeLine to prepare and retain a topnotch, diverse scientific workforce, increasingly necessary if the market for biomedical researchers trainees should be introduced to multiple career paths, according to strengthens outside of the United States in coming years). a June report by the niH biomedical Workforce Working Group. One of those options—the staff scientist—could use a boost. Co-chaired Today, these scientists bring stability to many labs and provide by Princeton University President shirley tilghman (see “the Future important functions as part of institutional core facilities, but have a of science,” HHMI Bulletin, May 2011) and sally rockey, niH deputy wide variety of titles and employment conditions.
    [Show full text]
  • Lasker Awards Honor Trailblazers in Medical Research and Public Service
    EMBARGOED FOR RELEASE UNTIL SEPTEMBER 14, 2009 FROM: The Albert and Mary Lasker Foundation New York, New York CONTACT: Rubenstein Communications, Inc. Charles Zehren 212-843-8590 [email protected] Janet Wootten 212-843-8032 [email protected] 2009 LASKER AWARDS HONOR TRAILBLAZERS IN MEDICAL RESEARCH AND PUBLIC SERVICE: John Gurdon and Shinya Yamanaka, for Breakthrough Research in Nuclear Reprogramming and Stem Cells Brian J. Druker, Nicholas B. Lydon and Charles L. Sawyers, for Lifesaving Discoveries in Treatment of Leukemia Michael R. Bloomberg, for Landmark Policy and Philanthropic Initiatives to Reduce Tobacco Use and Foster Public Health New York, Sept. 13, 2009 - The Albert and Mary Lasker Foundation, which for 64 years has championed the greatest breakthroughs in medical research, today announced the winners of the 2009 Lasker Awards for outstanding accomplishments in basic medical and clinical medical research, and public service. The three awards—recognized as the most prestigious medical research awards in the United States today— honor six visionaries whose insight and courage has led to dramatic advances that will prevent disease and prolong life. John Gurdon of Cambridge University and Shinya Yamanaka of Kyoto University will receive the 2009 Albert Lasker Basic Medical Research Award for breakthrough discoveries into the process that instructs specialized adult cells to form stem cells. Brian J. Druker of Oregon Health & Science University, Nicholas B. Lydon, formerly of Novartis, and Charles L. Sawyers of Memorial Sloan-Kettering Cancer Center will receive the 2009 Lasker~DeBakey Clinical Medical Research Award for groundbreaking work on the treatment of chronic myeloid leukemia. New York City Mayor Michael R.
    [Show full text]